Amunix Pharmaceuticals snaps up $117m Series B

Amunix Pharmaceuticals Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has raised $117 million in Series B financing.

4 March 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles